



MARKET RELEASE

28 November 2012

Starpharma Holdings Limited

TRADING HALT

The securities of Starpharma Holdings Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 30 November 2012 or when the announcement is released to the market.

Security Code: SPL

Alexandra Pigdon
Adviser, Listings (Melbourne)



28 November 2012

Attention: Alexandra Pigdon
Adviser, Listings (Melbourne)

ASX Markets Supervision Pty Ltd
Level 4
North Tower
525 Collins Street
Melbourne VIC 3000
(by email)

Dear Alexandra,

Starpharma Holdings Limited (ASX:SPL) – Request for a trading halt

In accordance with Listing Rule 17.1, Starpharma Holdings Limited (**Starpharma**) requests a trading halt in its securities pending an announcement to the market regarding the results of the Company's two phase 3 studies of VivaGel® for the treatment of bacterial vaginosis. Starpharma expects that the announcement will be made prior to the opening of trading on Thursday, 29 November 2012.

Accordingly, the trading halt should remain in place until the earlier of the opening of trading on Thursday, 29 November 2012 or when Starpharma makes an announcement in relation to the study results.

Starpharma is not aware of any reason why the trading halt should not be granted by ASX.

Yours sincerely,

Ben Rogers
Company Secretary